Design Therapeutics, Inc. filed its quarterly report on Form 10-Q with the SEC on November 4, 2026, covering the fiscal quarter ended September 30, 2026.

Key Highlights

  • Shares outstanding: As of October 30, 2026, the company reported 64,036,280 shares of common stock outstanding.
  • Filing status: Design Therapeutics is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company.
  • Extended transition period: The company has elected not to use the extended transition period for complying with new or revised financial accounting standards under Section 13(a) of the Exchange Act.
  • Clinical stage: According to the filing, the company has three product candidates in clinical development, with all other research programs in nonclinical or discovery stages.
  • No revenue: The filing discloses that the company has incurred net losses since inception and anticipates continuing to incur significant losses for the foreseeable future.
  • Exchange listing: The company's common stock trades on NASDAQ:DSGN, listed on The Nasdaq Global Select Market.

Design Therapeutics Q3 2026: Clinical-Stage Operations and Financial Position

Design Therapeutics, Inc. (NASDAQ:DSGN) submitted its Form 10-Q for the quarterly period ended September 30, 2026, disclosing operational and risk information for the period. The Carlsbad, California-based company, incorporated in Delaware, reported 64,036,280 shares of common stock outstanding as of October 30, 2026, at a par value of $0.0001 per share.

According to the filing, the company remains in the clinical development phase, with three product candidates in clinical trials and all remaining research programs at the nonclinical or discovery stage. The filing specifically references a program in Friedreich ataxia, noting forward-looking expectations around clinical development and data announcements for a candidate identified as DT-216P2. The company disclosed that it "has incurred net losses since our inception" and anticipates continued significant losses, with no guarantee of ever generating revenue or achieving profitability.

The filing identifies several material risks, including the company's limited operating history, the lengthy and expensive nature of nonclinical and clinical development, the novel nature of its product candidate technologies, and the possibility of undesirable side effects that could delay or prevent regulatory approval. The company notes that forward-looking statements in the quarterly report are subject to known and unknown risks and uncertainties, and cautions readers not to place undue reliance on them. All such statements reflect the company's own characterizations and are subject to its cautionary language.

What Was Disclosed

Design Therapeutics filed its Q3 2026 Form 10-Q covering the period ended September 30, 2026, disclosing 64,036,280 shares outstanding, its clinical-stage status with three programs in trials, and ongoing net losses since inception.